3D Mol Similar

Amlodipine

: Iupac Name：3-O-ethyl 5-O-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate; CAS No.: 88150-42-9; Molecular Weight：408.8759; Modify Date.: 2023-03-13 12:37; Introduction: Amlodipine, 2-[, for the treatment of hypertension. Amlodipineis also marketed as a combination therapy with atorvastatinunder the tradename Norvasc for the management of highcholesterol and high blood pressure. View more+

Request For Quotation

1. Names and Identifiers

: 1.1 Name; Amlodipine; 1.2 Synonyms; (R)-3-ethyl 5-methyl 2 (R,S)-2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine 2-[(2-Aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylic acid 3-ethyl 5-methyl Ester 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine 3,5-Pyridinedicarboxylic acid, 2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester 3,5-Pyridinedicarboxylic acid, 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester 3,5-Pyridinedicarboxylic acid, 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 5-ethyl 3-methyl ester 3,5-pyridinedicarboxylicacid,1,4-dihydro-2-((2-aminoethoxy)methyl)-4-(2-chlor 3-ethyl 5-methyl ()-2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridine dicarboxylate 3-Ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydro-3,5-pyridinedicarboxylate 3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate 3-Ethyl 5-methyl 2-{[(2-aminoethyl)oxy]methyl}-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate 3-ethyl-5-methyl-(4RS)-2-[(2-aminoethoxy)-methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-carboxylate benzene sulphonate 3-ethyl5-methylester 5-Ethyl 3-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydro-3,5-pyridinedicarboxylate Amlocard AMLODIPINE BASE Amlodipine base (crystalline) Amlodipino Amlodipinum Amlodipinum [Latin] Amlodis Coroval Istin Lipinox LOTREL methyl ethyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate MFCD00864687 Norvasc T6M DHJ B1O2Z CVO2 DR BG& EVO1 F1 UNII:1J444QC288; View all

1.3 CAS No.: 88150-42-9

1.4 CID: 2162

1.5 EINECS(EC#): 618-119-7

1.6 Molecular Formula: C20H25ClN2O5 (isomer)

1.7 Inchi: InChI=1S/C20H25ClN2O5/c1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21/h5-8,17,23H,4,9-11,22H2,1-3H3

1.8 InChIkey: HTIQEAQVCYTUBX-UHFFFAOYSA-N

1.9 Canonical Smiles: CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN

1.10 Isomers Smiles: CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN

2. Properties

2.1 Density: 1.227

2.1 Melting point: 178-179℃

2.1 Boiling point: 527.2 °C at 760 mmHg

2.1 Refractive index: 1.546

2.1 Flash Point: 527.2 °C at 760 mmHg

2.1 Precise Quality: 408.14500

2.1 PSA: 99.88000

2.1 logP: 3.29540

2.1 Solubility: 75.3 mg/L

2.2 Appearance: Yellow Solid

2.3 Storage: -20°C Freezer

2.4 Chemical Properties: Yellow Solid

2.5 Color/Form: Yellow powder

2.6 Decomposition: Hazardous decomposition products formed under fire conditions - Carbon oxides, nitrogen oxides (NOx), sulfur oxides, hydrogen chloride gas. /Amlodipine besylate/

2.7 pKa: pKa 8.6 (Uncertain)

2.8 Water Solubility: H2O: 75.3 mg/L

2.9 Stability: Stable under recommended storage conditions. /Amlodipine besylate/

2.10 StorageTemp: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C

3. Use and Manufacturing

3.1 Definition: ChEBI: A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.

3.2 General Description: Amlodipine, 2-[, for the treatment of hypertension. Amlodipineis also marketed as a combination therapy with atorvastatinunder the tradename Norvasc for the management of highcholesterol and high blood pressure.

3.3 Methods of Manufacturing: (R, S)-Amlodipine besylate (5.342 g) was suspended in water (100 mL). The resultant mixture was brought to reflux while stirring. NaOH (0.4 g) was added to the resultant yellow solution, and the solution was allowed to reflux for a further 30 minutes. The mixture was subsequently allowed to cool overnight, and the resultant precipitate was filtered and dried under vacuum to provice 3.41 g (88.6 percent yield) of amlodipine (free base). Melting point 133-138Stage -3: Preparation of Amlodipine from Phthalimido amlodipine:Pure Phthalimido amlodipine (50 g) prepared as above is suspended in ethanolic methylamine (600 ml) and maintained for 17 hrs at 28°C - 32°C. The reaction mass is slowly poured into hot water (1200 ml) held at 50°C - 55°C over 45 min and mixed for about 1 hr at 50°C - 55°C. Reaction mass is slowly cooled and maintained for about 1 hr at 20°C - 25°C. The precipitated solid is filtered, washed the wet cake with water. Dried the product at 55°C - 60°C till constant weight.Dry weight of the Amlodipine base is 33.0 g (Yield: 87.2percent).Preparation of 3-Ethyl, 5-methyl (4RS) 2-[(2-AMINOETHOXY) METHYLL-4-(2-CHLOROPHENYL)-6-METHYL-1, 4-dihydro pyridine-3, 5-dicarboxylate (IV) A 100 L reactor was charged with 7.0 kg of phthaloyl amlodipine and 33.5 kg of toluene. Hydrazine hydrate 5. 1 kg was mixed with 10.0 kg of methanol in a 25 L reactor and was added into the stirring suspension of phthaloyl amlodipine at 22-24 °C. The solution was stirred for 7h at this temperature. The solid material phthalhydrazide was filtered off. The organic phase was washed with 2 X 20 L of MGSOI7 H20. After separating the phases, organic phase dried over 1.28 kg of MGS04 and filtered. The solution was concentrated to 1/3 of its original volume and 24 kg of n-hexanes was added. The mixture was cooled down to 0- 5 °C and kept at this temperature for 2h with stirring and then 12h without stirring. The product was filtered off and dried in oven under vacuum at 55 °C for 12h to give 4.6 kg of amlodipine base in 86.5percent yield as AWHITE POWDER. LH-NMR (CDC13) 6 7.85 (s, 1H), 7.20 (m, 4H), 5. 38 (s, 1H), 4.78 (d, 1H), 4.70 (d, 1H), 3.95 (m, 2H), 3.60 (s, 3H), 3.57 (d, 2H), 2.95 (M, 2H), 2.34 (s, 3H), 1.17 (t, 3H). 13C-NMR (CDCL3) No. 168.3, 167.4, 157.1, 146.2, 146.1, 144.6, 132.5, 131.7, 129.4, 127.5, 127.0, 104.0, 101.5, 73.5, 68.2, 60.0, 51.0, 41.3, 37.3, 19. 4, 14.5.General procedure: To a 50-ml glass round-bottom flask was added sequentially the primary amine 2 (1.0 mmol; aliphatic, aromatic or heteroaromatic; as free naked amine or as HCl, MsOH, TsOH or tartrate salt), FSO2N3 solution (containing 1.0 mmol FSO2N3, approximately 200 mM in DMF/MTBE 1:1, v/v, approximately 5 ml, volume adjusted according to the concentration; prepared according to the above procedure and diluted with equal volume of DMF) and aqueous KHCO3 solution (3.0 M, 1.33 ml, containing 4.0 mmol KHCO3). The reaction mixture was stirred for 5 min at room temperature, while monitoring by LC-MS. After completion, EtOAc (40 ml) was added and the mixture was washed sequentially with brine (60 ml × 6), water (60 ml × 2) and brine (60 ml), dried over Na2SO4, concentrated by rotary evaporation and dried under vacuum to afford the azide product 3. For products containing acidic functional groups, this extraction process was modified with acidified aqueous phase (acidified with aqueous HCl). Detailed procedures and the various modifications, as well as the characterization data for each compound, can be found in Supplementary Information 1.Accurately referred to as compound S23 take 500mg of 2.34mmol ie, dissolved in acetonitrile and added 1.0g About 2.53mmol amlodipine, i.e., 3-ethyl-5-methyl-2 - ((2-amino) methyl) -4- (2- Chloro) -6-methyl-1, 4-dihydropyridine-3, 5-dicarboxylic acid ester, 1.04g of potassium carbonate powder and about 7.59mmol 35a catalytic amount of about 0.23mmol mg NaI, the reaction system was transferred to 80 C in an oil bath at reflux, TLC Tracking and monitoring, 16h After completion of the reaction, the reaction was stopped, the organic solvent is evaporated, the reaction mixture was subjected to silica Gel column chromatography chromatography using the elution system containing 1% triethylamine, eluent petroleum ether and wherein Ethyl acetate in a volume ratio of 2:1-1:1 elution gradient, to give the compound of the present invention provides 7, 750mg, 54.1% yield.; View all

3.4 Usage: A dihydropyridine calcium channel blocker; activity resides mainly in the (-)-isomer.

4. Safety and Handling

4.1 Hazard Class: IRRITANT

4.1 Hazard Declaration: H301

4.1 Safety Profile: Human systemic effects. Whenheated to decomposition it emits toxic vapors of NOx andCl-. Amlodipine Preparation Products And Raw materials Raw materials

4.2 Caution Statement: P260, P264, P270, P273, P280, P301+P310, P305+P351+P338, P310, P314, P321, P330, P391, P405, P501

4.2 RTECS: US7968329

4.2 Specification

The Amlodipine with the cas number 88150-42-9, is also called (1)3-Ethyl-5-methyl ( -)-2-((2-aminoethoxy)methyl)-4-(2-chlorphenyl)-1,4-dihydro-6-methyl-3,5-pyridindicarboxylat ; (2)3-Ethyl-5-methyl ( -)-2-((2-aminoethoxymethyl)-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate ; (3) Amlocard ; (4) Amlodipine ; (5) Amlodipino ; (6) Amlodipinum ; (7) Amlodis ; (8) Amlor ; (9) Coroval ; (10) Lipinox ; (11) Norvasc. It belongs to the following product categories: (1)Active Pharmaceutical Ingredients; (2)Dihydropyridine Class Chemicals; (3)Intermediates & Fine Chemicals; (4)Pharmaceuticals; (5)Calcium channel

Properties of Amlodipine are: (1)ACD/LogP: 4.16 ; (2)# of Rule of 5 Violations: 0 ; (3)ACD/LogD (pH 5.5): 1.23 ; (4)ACD/LogD (pH 7.4): 2.64 ; (5)ACD/BCF (pH 5.5): 1 ; (6)ACD/BCF (pH 7.4): 26.11 ; (7)ACD/KOC (pH 5.5): 5.14 ; (8)ACD/KOC (pH 7.4): 133.65 ; (9)#H bond acceptors: 7 ; (10)#H bond donors: 3 ; (11)#Freely Rotating Bonds: 11 ; (12)Polar Surface Area: 68.31??²; (13)Index of Refraction: 1.545 ; (14)Molar Refractivity: 105.41 cm³ ; (15)Molar Volume: 333 cm³ ; (16)Polarizability: 41.79 ×10^-24cm³ ; (17)Surface Tension: 44.4 dyne/cm ; (18)Density: 1.227 g/cm³ ; (19)Flash Point: 272.6 °C ; (20)Enthalpy of Vaporization: 80.17 kJ/mol ; (21)Boiling Point: 527.2 °C at 760 mmHg ; (22)Vapour Pressure: 3.34E-11 mmHg at 25°C

The Amlodipine appears to be Yellow Solid. It is used as an anti-hypertensive and in the treatment of angina because it is a long-acting calcium channel blocker. Seemimg Like other calcium channel blockers, Amlodipine reduce blood pressure by relaxing the smooth muscle in the arterial wall, decreasing peripheral resistance. Besides, it increases blood flow to the heart muscle in angina. Adverse effcts include common headache, fatigue, insomnia, edema, abdominal pain, nausea, dizziness, palpitation and red face. Rare rash, itching, expiratory dyspnea, muscle spasm and indigestion. Rarely have myocardial infarction and chest. It can have edema, headache, dizziness, weakness, etc.

The Amlodipine can react with nicotinic acid to obtain 4-(2-chloro-phenyl)-2-methyl-6-{2-[(pyridine-3-carbonyl)-amino]-ethoxymethyl}-1,4-dihydro-pyridine-3,5-dicarboxylic acid 5-ethyl ester 3-methyl ester.
Reaction condition is CH2Cl2 as solvent under ambient temperature for 16 hour(s). Yield is 57 %.
?????????????????
?

You can still convert the following datas into molecular structure :
1. SMILES: Clc1ccccc1C2C(=C(/N/C(=C2/C(=O)OCC)COCCN)C)\C(=O)OCCopyCopied
2. InChI:?InChI=1/C20H25ClN2O5/c1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21/h5-8,17,23H,4,9-11,22H2,1-3H3

The Amlodipine toxic data can be showed in the following sheet.
?

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
child	TDLo	oral	400ug/kg (0.4mg/kg)	VASCULAR: BP LOWERING NOT CHARACTERIZED IN AUTONOMIC SECTION	American Journal of Emergency Medicine. Vol. 18, Pg. 581, 2000.
women	LDLo	oral	1400ug/kg (1.4mg/kg)	CARDIAC: PULSE RATE INCREASE WITHOUT FALL IN BP VASCULAR: BP LOWERING NOT CHARACTERIZED IN AUTONOMIC SECTION	Journal of Toxicology, Clinical Toxicology. Vol. 33, Pg. 253, 1995.
women	TDLo	oral	600ug/kg/3D-I (0.6mg/kg)	SENSE ORGANS AND SPECIAL SENSES: OTHER CHANGES: OLFACTION BLOOD: HEMORRHAGE BLOOD: THROMBOCYTOPENIA	Annals of Pharmacotherpy. Vol. 33, Pg. 1126, 1999.

View all

4.3 Toxicity: TDLo orl-chd: 400 mg/kg:BPR AJEMEN 18,581,2000

5. MSDS

2.Hazard identification

2.1 Classification of the substance or mixture

Acute toxicity - Oral, Category 3

Serious eye damage, Category 1

Specific target organ toxicity \u2013 repeated exposure, Category 2

Hazardous to the aquatic environment, short-term (Acute) - Category Acute 1

Hazardous to the aquatic environment, long-term (Chronic) - Category Chronic 1

2.2 GHS label elements, including precautionary statements

Pictogram(s)
Signal word	Danger
Hazard statement(s)	H301 Toxic if swallowed H318 Causes serious eye damage H373 May cause damage to organs through prolonged or repeated exposure H400 Very toxic to aquatic life H410 Very toxic to aquatic life with long lasting effects
Precautionary statement(s)
Prevention	P264 Wash ... thoroughly after handling. P270 Do not eat, drink or smoke when using this product. P280 Wear protective gloves/protective clothing/eye protection/face protection. P260 Do not breathe dust/fume/gas/mist/vapours/spray. P273 Avoid release to the environment.
Response	P301+P310 IF SWALLOWED: Immediately call a POISON CENTER/doctor/\u2026 P321 Specific treatment (see ... on this label). P330 Rinse mouth. P305+P351+P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P310 Immediately call a POISON CENTER/doctor/\u2026 P314 Get medical advice/attention if you feel unwell. P391 Collect spillage.
Storage	P405 Store locked up.
Disposal	P501 Dispose of contents/container to ...

2.3 Other hazards which do not result in classification

none

View all

6. Synthesis Route

88150-42-9Total: 7 Synthesis Route

638-07-3 228 Suppliers

88150-42-9 316 Suppliers

Literatures:
Journal of Medicinal Chemistry, , vol. 29, # 9 p. 1696 - 1702
Yield: null

88150-62-3 106 Suppliers

88150-42-9 316 Suppliers

Literatures:
MATRIX LABORATORIES LTD Patent: WO2006/3672 A1, 2006 ; Location in patent: Page/Page column 7 ;
Yield: ~90%

88150-46-3 2 Suppliers

88150-42-9 316 Suppliers

Literatures:
Journal of Medicinal Chemistry, , vol. 29, # 9 p. 1696 - 1702
Yield: null

View all

7. Precursor and Product

precursor:

88150-46-3

638-07-3

88150-75-8

111470-99-6

120289-15-8

88150-62-3

88150-45-2

product :

88150-47-4

111470-99-6

103129-82-4

103129-81-3

8. Other Information

8.0 Usage: A calcium channel antagonist with potent antioxidant activityAmlodipine is an L-type calcium channel protein inhibitor and blocker. It is used in combination with the angiotensin receptor blocker olmesartan. Further, it acts as a dihydropyridine calcium channel blocker. It is used as an anti-hypertensive. It is involved in the treatment of angina and to lower blood pressure. In addition to this, it is used to prevent chest pain and in coronary artery disease.

8.1 Description: Amlodipine is a dihydropyridine L-type calcium channel blocker that selectively inhibits calcium influx in cardiac and vascular smooth muscle. Acting as a vasodilator, amlodipine reduces blood pressure by relaxing the smooth muscle in the arterial wall, decreasing total peripheral resistance. It inhibits calcium-induced contractions in depolarized rat aorta with an IC₅₀ value of 1.9 nM, displaying a slow rate of association and dissociation in isolated vascular and cardiac tissues. Amlodipine also demonstrates actions independent of L-type calcium channel blockade by regulating membrane fluidity and cholesterol deposition, stimulating nitric oxide production, acting as an antioxidant, and regulating matrix deposition in vitro and in vivo. Formulations containing amlodipine have been used in the treatment of hypertension.; View all

8.2 Chemical Properties: Yellow Solid

8.3 Uses: A dihydropyridine calcium channel blocker; activity resides mainly in the (-)-isomer.

8.4 Uses: anti-hypertensive;calcium channel blocker

8.5 Uses: A deuterated dihydropyridine calcium channel blocker.;Application of Labeled APIs: Labeled Amlodipine, intended for use as an internal standard for the quantification of Amlodipine by GC- or LC-mass spectrometry.

8.6 Definition: ChEBI: A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.

8.7 Brand name: Norvasc (Pfizer).

8.8 General Description: Amlodipine, 2-[, for the treatment of hypertension. Amlodipineis also marketed as a combination therapy with atorvastatinunder the tradename Norvasc for the management of highcholesterol and high blood pressure.

8.9 Hazard: Human systemic effects.

8.10 Safety Profile: Human systemic effects. Whenheated to decomposition it emits toxic vapors of NOx andCl^-.

8.11 Storage Conditions: (R, S)-Amlodipine besylate (5.342 g) was suspended in water (100 mL). The resultant mixture was brought to reflux while stirring. NaOH (0.4 g) was added to the resultant yellow solution, and the solution was allowed to reflux for a further 30 minutes. The mixture was subsequently allowed to cool overnight, and the resultant precipitate was filtered and dried under vacuum to provice 3.41 g (88.6 percent yield) of amlodipine (free base). Melting point 133-138Stage -3: Preparation of Amlodipine from Phthalimido amlodipine:Pure Phthalimido amlodipine (50 g) prepared as above is suspended in ethanolic methylamine (600 ml) and maintained for 17 hrs at 28°C - 32°C. The reaction mass is slowly poured into hot water (1200 ml) held at 50°C - 55°C over 45 min and mixed for about 1 hr at 50°C - 55°C. Reaction mass is slowly cooled and maintained for about 1 hr at 20°C - 25°C. The precipitated solid is filtered, washed the wet cake with water. Dried the product at 55°C - 60°C till constant weight.Dry weight of the Amlodipine base is 33.0 g (Yield: 87.2percent).Preparation of 3-Ethyl, 5-methyl (4RS) 2-[(2-AMINOETHOXY) METHYLL-4-(2-CHLOROPHENYL)-6-METHYL-1, 4-dihydro pyridine-3, 5-dicarboxylate (IV) A 100 L reactor was charged with 7.0 kg of phthaloyl amlodipine and 33.5 kg of toluene. Hydrazine hydrate 5. 1 kg was mixed with 10.0 kg of methanol in a 25 L reactor and was added into the stirring suspension of phthaloyl amlodipine at 22-24 °C. The solution was stirred for 7h at this temperature. The solid material phthalhydrazide was filtered off. The organic phase was washed with 2 X 20 L of MGSOI7 H20. After separating the phases, organic phase dried over 1.28 kg of MGS04 and filtered. The solution was concentrated to 1/3 of its original volume and 24 kg of n-hexanes was added. The mixture was cooled down to 0- 5 °C and kept at this temperature for 2h with stirring and then 12h without stirring. The product was filtered off and dried in oven under vacuum at 55 °C for 12h to give 4.6 kg of amlodipine base in 86.5percent yield as AWHITE POWDER. LH-NMR (CDC13) 6 7.85 (s, 1H), 7.20 (m, 4H), 5. 38 (s, 1H), 4.78 (d, 1H), 4.70 (d, 1H), 3.95 (m, 2H), 3.60 (s, 3H), 3.57 (d, 2H), 2.95 (M, 2H), 2.34 (s, 3H), 1.17 (t, 3H). 13C-NMR (CDCL3) No. 168.3, 167.4, 157.1, 146.2, 146.1, 144.6, 132.5, 131.7, 129.4, 127.5, 127.0, 104.0, 101.5, 73.5, 68.2, 60.0, 51.0, 41.3, 37.3, 19. 4, 14.5.General procedure: To a 50-ml glass round-bottom flask was added sequentially the primary amine 2 (1.0 mmol; aliphatic, aromatic or heteroaromatic; as free naked amine or as HCl, MsOH, TsOH or tartrate salt), FSO2N3 solution (containing 1.0 mmol FSO2N3, approximately 200 mM in DMF/MTBE 1:1, v/v, approximately 5 ml, volume adjusted according to the concentration; prepared according to the above procedure and diluted with equal volume of DMF) and aqueous KHCO3 solution (3.0 M, 1.33 ml, containing 4.0 mmol KHCO3). The reaction mixture was stirred for 5 min at room temperature, while monitoring by LC-MS. After completion, EtOAc (40 ml) was added and the mixture was washed sequentially with brine (60 ml × 6), water (60 ml × 2) and brine (60 ml), dried over Na2SO4, concentrated by rotary evaporation and dried under vacuum to afford the azide product 3. For products containing acidic functional groups, this extraction process was modified with acidified aqueous phase (acidified with aqueous HCl). Detailed procedures and the various modifications, as well as the characterization data for each compound, can be found in Supplementary Information 1.Accurately referred to as compound S23 take 500mg of 2.34mmol ie, dissolved in acetonitrile and added 1.0g About 2.53mmol amlodipine, i.e., 3-ethyl-5-methyl-2 - ((2-amino) methyl) -4- (2- Chloro) -6-methyl-1, 4-dihydropyridine-3, 5-dicarboxylic acid ester, 1.04g of potassium carbonate powder and about 7.59mmol 35a catalytic amount of about 0.23mmol mg NaI, the reaction system was transferred to 80 C in an oil bath at reflux, TLC Tracking and monitoring, 16h After completion of the reaction, the reaction was stopped, the organic solvent is evaporated, the reaction mixture was subjected to silica Gel column chromatography chromatography using the elution system containing 1% triethylamine, eluent petroleum ether and wherein Ethyl acetate in a volume ratio of 2:1-1:1 elution gradient, to give the compound of the present invention provides 7, 750mg, 54.1% yield.; View all

9. Computational chemical data

Molecular Weight: 408.8759g/mol
Molecular Formula: C₂₀H₂₅ClN₂O₅
Compound Is Canonicalized: True
XLogP3-AA: null
Exact Mass: 408.1451996
Monoisotopic Mass: 408.1451996
Complexity: 647
Rotatable Bond Count: 10
Hydrogen Bond Donor Count: 2
Hydrogen Bond Acceptor Count: 7
Topological Polar Surface Area: 99.9
Heavy Atom Count: 28
Defined Atom Stereocenter Count: 0
Undefined Atom Stereocenter Count: 1
Defined Bond Stereocenter Count: 0
Undefined Bond Stereocenter Count: 0
Isotope Atom Count: 0
Covalently-Bonded Unit Count: 1
CACTVS Substructure Key Fingerprint: AAADceB7OAAEAAAAAAAAAAAAAAAAAAAAAAAwQAAAAAAAAAABAAAAHgIQAAAADQrhmCYyCILABACIAiTSSAACAAAgBQAIiIEAAsgKJDKBMxCDMAAkkACYqUeI7uiOgAAAAAABAAAAAAAAAAIAAAAAAAAAAA==

10. Question & Answer

Have you ever wondered about the applications and effects of Amlodipine in pharmaceuticals? Oct 29 2023
Amlodipine is a commonly used drug ingredient, belonging to the class of calcium channel blockers. It has various applications and effects in the pharmaceutical field, and in this article, we will exp..
Why is Amlodipine so popular? Oct 11 2022
Amlodipine, a third-generation dihydropyridine calcium channel blocker, is a typical drug in the alkaline, long-acting dihydropyridine calcium channel blocker class. It acts on the dihydropyridine bi..
Who is Amlodipine suitable for? Sep 08 2021
Amlodipine is a calcium channel blocker primarily used for the treatment of hypertension and coronary artery disease. It is important to pay attention to the dosage, contraindications, precautions, a..
What should be noted when taking Amlodipine? Aug 26 2021
Amlodipine is highly effective in treating hypertension and angina during daily use. Understanding the precautions after taking this medication can help ensure safety and achieve better results in ma..